Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase. Particularly, modified-release formulations comprising an alkaline phosphatase are provided, which release a substantial amount of the alkaline phosphatase in the intestines. Therapeutic uses of the alkaline phosphatase formulations are also provided.

Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Abstract: A method of making a part by an additive manufacturing process includes the steps of: (a) supporting a build platform on a support surface; (b) traversing a powder dispenser positioned above the support surface across the build platform, while dispensing powder from the powder dispenser, so as to deposit the powder over the build platform; (c) traversing the build platform with a scraper to scrape the deposited powder, so as to form a layer increment of powder; (d) using a directed energy source to fuse the layer increment of powder in a pattern corresponding to a cross-sectional layer of the part; and (e) repeating in a cycle steps (b) through (d) to build up the part in a layer-by-layer fashion.

Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

Abstract: A method of making a part by an additive manufacturing process includes the steps of: (a) supporting a build platform on a support surface; (b) traversing a powder dispenser positioned above the support surface across the build platform, while dispensing powder from the powder dispenser, so as to deposit the powder over the build platform; (c) traversing the build platform with a scraper to scrape the deposited powder, so as to form a layer increment of powder; (d) using a directed energy source to fuse the layer increment of powder in a pattern corresponding to a cross-sectional layer of the part; and (e) repeating in a cycle steps (b) through (d) to build up the part in a layer-by-layer fashion.

Abstract: An additive manufacturing apparatus includes: a support surface configured to support a build platform thereon; a powder dispenser disposed above the support surface, the powder dispenser configured to dispense powder, and movable laterally over the support surface; a scraper moveable over the build platform and configured to scrape powder dispensed thereon by the powder dispenser, so as to provide a layer increment of powder above the build platform; and a directed energy source configured to melt and fuse the layer increment of powder in predetermined pattern so as to form a part.

Abstract: An additive manufacturing apparatus includes: a support surface configured to support a build platform thereon; a powder dispenser disposed above the support surface, the powder dispenser configured to dispense powder, and movable laterally over the support surface; a scraper moveable over the build platform and configured to scrape powder dispensed thereon by the powder dispenser, so as to provide a layer increment of powder above the build platform; and a directed energy source configured to melt and fuse the layer increment of powder in predetermined pattern so as to form a part.

Abstract: A system and method of altering damaged mammalian skin using a multiphoton processes is disclosed. A femtosecond laser initiates a multiphoton event using pulse energies of 2-5 mJ thereby causing multiphoton ablation without damaging surrounding tissue. The laser is focused to the vicinity of a target organelle that occurs naturally within the damaged skin, and is related to the dermatological condition being addressed. The type of organelle depends on the condition being addressed, and may be targeted by the depth beneath the surface of the skin at which it is located. The femtosecond laser beam is focused to an intensity of least 1012 W/cm2 to initiate the multiphoton event transforms the targeted organelle to mitigate the damage to the skin.

Abstract: A system and method of altering damaged mammalian skin using a multiphoton processes is disclosed. A femtosecond laser initiates a multiphoton event using pulse energies of 2-5 mJ thereby causing multiphoton ablation without damaging surrounding tissue. The laser is focused to the vicinity of a target organelle that occurs naturally within the damaged skin, and is related to the dermatological condition being addressed. The type of organelle depends on the condition being addressed, and may be targeted by the depth beneath the surface of the skin at which it is located. The femtosecond laser beam is focused to an intensity of least 1012 W/cm2 to initiate the multiphoton event transforms the targeted organelle to mitigate the damage to the skin.